Ascendis Pharma A/S (NASDAQ:ASND) PT Raised to $167.00 at JPMorgan Chase & Co.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target lifted by investment analysts at JPMorgan Chase & Co. from $165.00 to $167.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has an "overweight" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s price target suggests a potential upside of 14.16% from the company's current price.

Other research analysts have also issued reports about the company. Citigroup upped their price objective on Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a "buy" rating in a report on Thursday, February 8th. Cantor Fitzgerald restated an "overweight" rating and issued a $173.00 price target on shares of Ascendis Pharma A/S in a research report on Monday. Jefferies Financial Group began coverage on Ascendis Pharma A/S in a research report on Wednesday, December 20th. They issued a "buy" rating and a $150.00 price target on the stock. Wedbush raised their price target on Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an "outperform" rating in a research report on Thursday, February 8th. Finally, StockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Monday, December 25th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $173.25.

Ascendis Pharma A/S Price Performance

NASDAQ ASND traded down $5.69 on Tuesday, reaching $146.29. The stock had a trading volume of 331,842 shares, compared to its average volume of 386,467. The firm has a fifty day moving average of $146.34 and a two-hundred day moving average of $119.60. Ascendis Pharma A/S has a 1-year low of $64.33 and a 1-year high of $161.00. The company has a market cap of $8.44 billion, a P/E ratio of -15.82 and a beta of 0.50.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) EPS for the quarter, beating analysts' consensus estimates of ($2.15) by $0.49. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. The firm had revenue of $148.62 million for the quarter, compared to analyst estimates of $97.02 million. Research analysts predict that Ascendis Pharma A/S will post -4.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC bought a new position in Ascendis Pharma A/S in the fourth quarter valued at about $25,000. SkyView Investment Advisors LLC acquired a new stake in shares of Ascendis Pharma A/S during the second quarter valued at about $66,000. US Bancorp DE boosted its stake in shares of Ascendis Pharma A/S by 35.2% during the fourth quarter. US Bancorp DE now owns 284 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 74 shares in the last quarter. Quadrant Capital Group LLC boosted its stake in shares of Ascendis Pharma A/S by 90.4% during the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 151 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 37.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company's stock valued at $42,000 after purchasing an additional 91 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.